x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:11:07

ASH 2025: Kite Pharma EVP Cindy Perettie discusses...

BiotechTV - News ·

2025/12/07

She highlights anito-cell's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T could be best in class in the future, and why Kite acquired an in vivo CAR-T company in August for $350M.

en-us

00:11:32

ASH 2025: Von Willibrand disease is the most common...

BiotechTV - News ·

2025/12/06

Founder and CEO Adam Rosenthal describes the unmet need for patients with this condition, and walks us through VGA039, a protein S modulator.

en-us

00:09:33

ASH 2025: Legend Biotech CEO Ying Huang discusses new...

BiotechTV - News ·

2025/12/06

He says he is confident in the commercial leadership profile that Carvykti has established, and walks us through potential follow-on pipeline programs.

en-us

00:15:18

Two veterans from MPM have launched a new VC firm...

BiotechTV - News ·

2025/12/05

Co-Founders Luke Evnin and Steven St. Peter describe the idea behind the firm, the value in partnering with philanthropies who know these diseases best, and why I&I is going through such a revolution currently.

en-us

00:15:19

Oxford, UK based Accession Therapeutics raised $40M...

BiotechTV - News ·

2025/12/04

Founder and CEO Bent Jakobsen describes the science behind the platform, which he believes is unique in that it is delivered systemically, but is designed to bypass healthy tissue and only target tumor cells (without the need for screening). It targets the integrin αvβ6.

en-us

00:16:04

From London: Cancer Research Horizons takes research...

BiotechTV - News ·

2025/11/26

CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty income to be reinvested in research. He describes the structure of the organization, a new startup fund, and some notable investments.

en-us

00:10:30

Jefferies London: Ipsen has done a string of deals...

BiotechTV - News ·

2025/11/19

He also goes over the company's programs in aesthetics, liver disease, and oncology.

en-us

00:11:17

Jefferies London: Terns' CEO Amy Burroughs previews...

BiotechTV - News ·

2025/11/19

The data has been accepted for an oral presentation on Monday, December 8 and will be followed by a company webcast with more info.

en-us

00:12:29

Jefferies London: Affinity Asset Advisors' Patrick...

BiotechTV - News ·

2025/11/19

He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes.

en-us

00:08:23

Jefferies London: Medicxi Announced a €500 Million...

BiotechTV - News ·

2025/11/19

He discusses the rationale behind the firm's asset-centric approach and highlights Vicebio as an example of how it works. Plus, his take on the current investment environment.

en-us

00:14:08

Jefferies London: Olema Oncology more than doubled...

BiotechTV - News ·

2025/11/19

Sean Bohen explains what he believes is the significance of the Roche announcement, and why he believes Olema's could potentially be a best in class oral SERD. Plus, a preview of data that will deliver sometime next year.

en-us

00:13:27

Jefferies London: Zealand Pharma CEO Adam Steensberg...

BiotechTV - News ·

2025/11/18

He discusses Zealand's partnership with Roche, and new data that will be coming next year. Plus, the company's partnership with Boehringer on survodutide.

en-us

00:09:25

Jefferies London: Nanobiotix has a new platform that...

BiotechTV - News ·

2025/11/18

CEO Laurent Levy introduces us to the company's Curadigm Nanoprimer platform and explains its potential use cases. Plus, an update on the company's JNJ partnership, and a recent royalty deal.

en-us

00:08:01

Jefferies London: Jefferies Global Chairman of...

BiotechTV - News ·

2025/11/18

He shares his take on the capacity for pharma to do more buying, and list his favorite areas of science, which include I&I, CNS/Neurology, and modalities such as bi-specifics and tri-specifics.

en-us

00:11:35

Jefferies London: Chief Scientific Officer Tony Wood...

BiotechTV - News ·

2025/11/18

He mentions momelotinib, Blenrep, B7-H3, depemokimab, efimosfermin, IL-33, TSLP, and more. Plus, GSK's dealmaking strategy.

en-us

00:10:41

Jefferies London: Zymeworks had double-news during...

BiotechTV - News ·

2025/11/18

CEO Kenneth Galbraith explains the new dual business focus and walks us through the topline HER2 data.

en-us

00:10:06

Jefferies London: Protagonist Therapeutics CEO Dinesh...

BiotechTV - News ·

2025/11/18

He covers the company's oral IL-23 (partnered with JNJ), rusfertide (partnered with Takeda), and a new early stage obesity program.

en-us

00:10:09

Jefferies London: BeOne Medicines announced a phase 3...

BiotechTV - News ·

2025/11/17

He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners.

en-us

00:10:26

Jefferies London: Sofinnova Partners announced a new...

BiotechTV - News ·

2025/11/17

Chairman and managing partner Antoine Papiernik tells us about the fund and how he expects to deploy it. Plus, the current state of European biotech.

en-us

00:04:41

Jefferies London: Jefferies M&A Banker Chris Roop...

BiotechTV - News ·

2025/11/17

He expects deals to continue in 2026, and says that the bidding wars we have seen recently are likely deal specific.

en-us

342 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter